All News
RheumNow’s expanded coverage of the #ACR20 Annual meeting is sponsored in part by @bmsnews, @HorizonNews, @SanofiGenzyme, @Novartis. All content chosen by RheumNow and its Faculty.
Dr. John Cush RheumNow ( View Tweet)
SEAM-RA trial Abst#0939 Combo TNF/MTX Rx -> ETN monoRx superior to MTX monoRx in sustaining remisson, simliar to staying on combo Rx. #ACR20 @RheumNow. Benefit of continuing combo: protect HACA Ab and longevity of TNFi https://t.co/Q934naKnBq
Eric Dein ejdein1 ( View Tweet)
@RheumNow #acr20 abs0654 we are what we eat: analysis of OmniHeart trial of pts w/HTN reveals DASH-patterns plant-based protein diet can also significantly lower sUA improves HTN &hyperlipidemia. Clincial trial of DASH plant protein based diet in gout would be interesting. https://t.co/5tQwiuwl84
Olga Petryna DrPetryna ( View Tweet)
Poll results are in... most chose upadacitinib followed by tofacitinib as their Jak-i of choice if insurance approval was not a factor in those that failed a bDMARD and remain on a cDMARD with high dz activity! @RheumNow @LCalabreseDO @ElaineHusniMD #ACR20 https://t.co/rl1nTqxzKg
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Dr Curtis presents SEAM-RA RCT of withdrawal of ETN or MTX in patients on combo therapy in sustained remission. 49.5% of ETN mono retained remission compared to 28.7% of MTX mono, and 52.9% who continued combo therapy. @rheumnow #ACR20 Abstr#939 #ACRbest https://t.co/wpAtBHJYUF
Richard Conway RichardPAConway ( View Tweet)
Low pre🤰c3/c4 levels assoc'd w/ ⬆ risk of adverse obstetric outcomes in women w/ aPL w/or w/o APS. Pts w/ triple+ aPL and ⬇ c3/c4 predicts a worse prognosis. @RheumNow #ACR20 https://t.co/Cd2TQBfXSe
sheila RHEUMarampa ( View Tweet)
@RheumNow #acr20 abs 0649 PROTECT trial of pegloticase in 7 kidney transplant pts w/uncontrolled gout: 2-12 infusions, 2+immunosuppressants on board for transplant care. No change in eGFR, HAQ pain ⬇️by 33.8 at wk20. Alb/cr improved by >35%in 2pts. sUA< 1 mg/dL, no serious AEs https://t.co/f4tnFjMTe8
Olga Petryna DrPetryna ( View Tweet)
#myositis & the ❤: lab tests
⬆ Trop = myocardial stress & injury, absence doesn't r/o myocarditis
BNP - utility unclear
There are no biomarkers specific for myocardial involvement
@RheumNow #ACR20 https://t.co/eyihKPoXSc
sheila RHEUMarampa ( View Tweet)
Does your pt have myocardial inflamm? Trop specific but not sensitive, BNP neither sens or specific. Consider EKG - sensitive (85%), but non-specific- But TTE is essential and cMRI is best! #ACR20 @RheumNow Great lecture from cardiologist, @HopkinsBayview APD https://t.co/6THm37KbQ3
Eric Dein ejdein1 ( View Tweet)
What happens long-term in Kawasaki disease now? Has IVIG availability fixed this?
Pop-based cohort, long follow-up.
Turns out cardiac event risk, whilst greatest early, continues >10y after - even in those w/o coronary aneurysms
@SickKidsNews @McMasterU #ACR20 ABST0937 @RheumNow https://t.co/1T6JmwhXNb
David Liew drdavidliew ( View Tweet)
Listen to part I of our #ACR20 Day 1 recap. Listen through the link below or find us on Apple podcasts.
https://t.co/W6EMQiF9Rf https://t.co/R1ieCFnIxz
Links:
Dr. John Cush RheumNow ( View Tweet)
Health plan claims data appears useful to classify inadequate responders in PsA and should be studied further. #ABS0898 #ACR20 @RheumNow https://t.co/jXBr54Fc6Z https://t.co/fAESyo5Uad
Dr. Rachel Tate uptoTate ( View Tweet)
Gender differences in Axial Spondyloarthritis patients Pooled data from 3 Ixekizumab studies Women: 1⃣older at disease onset (30 vs. 26) 2⃣Longer symptom duration (17.8 yrs vs. 16.7 yrs) 3⃣More peripheral joint pain and lower HLA-B27 @RheumNow #ACR20 Abs#0876 https://t.co/qGHXApi0Ko
Robert B Chao, MD doctorRBC ( View Tweet)
@andreafava representing @jhrheumatology @HopkinsBayview at plenary session! Urine proteomic biomarkers can revolutionize the way we see LN, and decrease need for renal Bx #Acr20 @RheumNow Abst#0936 https://t.co/zGoqmBPddT
Eric Dein ejdein1 ( View Tweet)
Can we use urine testing ( and all the cells, proteins, complements, DNA, rna) to predict LN response? Plenary II @SalemAlmaani @BradRovin @RheumNow #ACR20 @OSUWexMed
alexa meara lexmeara ( View Tweet)
Great talk #ACR20 Integrating bulk and single-cell RNA-sequencing @Kahlenberglab identifies clinically actionable 5-gene signatures that can effectively differentiate DM from cutaneous lupus lesions. @RheumNow @UMIntMed Also out in @JCI_insight https://t.co/uYS6OJH0Hf https://t.co/KR0wwDb5BK
Yu (Ray) Zuo RayZuoMD ( View Tweet)
Dr. J. Berquist @BolekBerqui shares her advice on an ideal online support network for patients (and, IMO, rheumatologists, too!) @RheumNow #ACR20 https://t.co/AFUiH7ihds
Dr. Rachel Tate uptoTate ( View Tweet)
Important things to take note of re: HBV reactivation (risk stratification and RR) when we consider therapies for our RA pts. 👇 @RheumNow #ACR20 #MedTwitter https://t.co/ZJfnZHpmfw
sheila RHEUMarampa ( View Tweet)
Another biosimilar Adalimumab. SB5 switch in RA, PsA & SpA N=354 No diff in effectiveness Some minor flares. Some changed dose unsure why. #ACR2020 @RheumNow @CRASCRRheum abstr#805 https://t.co/2Zb4H2jBXQ
Janet Pope Janetbirdope ( View Tweet)
Liver damage is NOT an extra-articular manifestation of RA BUT the ff'g factors are associated with liver disease in RA & can complicate management👇@RheumNow #ACR20 https://t.co/RqL69iVJpC
sheila RHEUMarampa ( View Tweet)
